AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
A profoundly deaf baby treated with Regeneron’s experimental gene therapy began hearing normally within six months, according to the company’s announcement. This data, presented at a medical conference, follows promising initial research from October. The baby, dosed at 11 months old, is one of the youngest to receive gene therapy for genetic deafness. A second patient, treated at age four, also showed hearing improvements after six weeks. Both children have a type of deafness caused by mutations in the otoferlin gene.
Keywords: hearing loss, gene therapy
@ 2024 . All rights reserved
@ 2024 . All rights reserved
Log in to MyLab and
download your gift voucher from the ‘Vouchers’ menu!
Thank you for your continued trust and partnership.
We look forward to serving you with excellence.